DBV Technologies shares fall 8.5% over the week, among the worst performers in the SBF 120
The Châtillon-based biotech closes the session near the bottom of the SBF 120, in a European market clearly trending downward. The stock extends its weekly decline while its US regulatory application continues to progress.
A sharper decline than the index, below the moving averages
The share of DBV Technologies falls 3.95% to €1.80, while the SBF 120 drops 1.56%. It ranks among the largest declines in the index, ahead of Inventiva and Nanobiotix among the most affected stocks.
The stock is below its 20-day moving average (MM20) at €1.84 (a gap of -2.28%) and below its 50-day moving average (MM50) at €1.90 (-5.37%), erasing during the session part of the rebound begun in early November. It is down 8.27% over the week but remains up 14.67% over one month.
The €1.57 support level is about 13% below the current price. Results for the last quarter also highlighted the fragility of its cash position: the group reported substantial doubt about its ability to continue as a going concern and a need for additional capital beyond the third quarter of 2027.
An FDA application under review and clinical data presented in the United States
The Viaskin Peanut patch is the subject of a Biologics License Application (BLA) for children aged 4 to 7, with priority review requested and an FDA decision expected in the fourth quarter of 2026, according to results published on October 28. The group plans a second filing, for children aged 1 to 3, in 2027.
On November 13, new analyses of the VITESSE study were presented at the ACAAI congress in Phoenix. They concern the severity of allergic reactions under treatment. The stock trades about 36% below its 200-day moving average (MM200) of €2.81, after a 24% decline over three months.
The next items to watch are the FDA decision expected by year-end and the company's financing needs.